Advertisement

Superiority of Interferon Gamma Assay Over Tuberculin Skin Test for Latent Tuberculosis in Inflammatory Bowel Disease Patients in Brazil

  • Renata F. Amorim
  • Eduardo R. C. Viegas
  • Antonio José V. Carneiro
  • Barbara C. Esberard
  • Evelyn S. Chinem
  • Raquel S. Correa
  • Luciana Rodrigues
  • Marcelo Ribeiro-Alves
  • Kelly S. Silva
  • Heitor S. de SouzaEmail author
  • Ana Teresa P. Carvalho
Original Article
  • 20 Downloads

Abstract

Background and Aims

To compare tuberculin skin test (TST) and interferon gamma release assay (IGRA) in the screening of LTBI among patients with inflammatory bowel disease (IBD) in an endemic area for tuberculosis, to evaluate the need for repeating tests during anti-TNFα, therapy, and to check whether the results may be affected by immunosuppression.

Methods

A cross-sectional study of 110 IBD patients and 64 controls was conducted in Rio de Janeiro, Brazil. The TST was administered after the Quantiferon(®)-TB Gold In-tube test was performed.

Results

TST and IGRA agreement was poor regarding diagnosis (kappa: control = 0.318; UC = 0.202; and CD = − 0.093), anti-TNFα therapy (kappa: with anti-TNFα = 0.150; w/o anti-TNFα = − 0.123), and immunosuppressive therapy (IST) (kappa: with IS = − 0.088; w/o IS = 0.146). Indeterminate IGRA was reported in four CD patients on IST. Follow-up tests after anti-TNFα identified conversion in 8.62% using TST and 20.0% using IGRA. Considering IGRA as a criterion standard, TST showed low sensitivity (19.05%) and positive predictive value (PPV) (21.05%). LTBI detection remarkably improved when IGRA was added to TST (sensitivity of 80.95% and PPV of 53.13%). Results were particularly relevant among CD patients where rates started from zero to reach sensitivity and PPV of more than 60%.

Conclusion

IGRA alone was more effective to detect LTBI than TST alone and had an overall remarkable added value as an add-on sequential test, particularly in CD patients. While cost-effectiveness of these strategies remains to be evaluated, IGRA appears to be justified in CD prior to and during anti-TNFα therapy, where tuberculosis is endemic.

Keywords

Inflammatory bowel disease Latent tuberculosis infection Tuberculin skin test Interferon gamma release assay 

Notes

Acknowledgment

The authors thank the Brazilian research foundations CNPq and FAPERJ for their financial support.

Author’s contribution

Amorim RF and Viegas ERC participated in the conception and design of the study, the acquisition, analysis, and interpretation of data, and the drafting of the manuscript; Chinem E, Correa RC, Rodrigues L, Ribeiro-Alves M, and Silva KS participated in the acquisition, analysis, and interpretation of the data, and the drafting of parts of the manuscript; Carneiro AJV and Esberard BC participated in the design of the study, analysis and interpretation of data, and critically revised the manuscript for important intellectual content; de Souza HSP and Carvalho ATP participated in the conception and design of the study, obtained funding, analyzed and interpreted data, and critically revised the manuscript for important intellectual content; all authors gave final approval of the submitted version of the manuscript.

Funding

This work was supported by grants from Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro-FAPERJ and Conselho Nacional de Desenvolvimento Científico e Tecnológico–CNPq.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to disclose.

References

  1. 1.
    Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med.. 2016;13:e1002152.CrossRefGoogle Scholar
  2. 2.
    Dheda K, Barry CE III, Maartens G. Tuberculosis. Lancet. 2016;387:1211–1226.CrossRefGoogle Scholar
  3. 3.
    Zumla A, George A, Sharma V, et al. The WHO 2014 global tuberculosis report–further to go. Lancet Glob Health. 2015;3:e10–12.CrossRefGoogle Scholar
  4. 4.
    WHO. Global tuberculosis report 2017 World Health Organization. 2017; http://www.who.int/tb/data/en/. Accessed 24 June 2018;147.
  5. 5.
    Menzies D. What does tuberculin reactivity after bacille Calmette-Guerin vaccination tell us? Clin Infect Dis. 2000;31:S71–74.CrossRefGoogle Scholar
  6. 6.
    Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10:1192–1204.PubMedGoogle Scholar
  7. 7.
    Taxonera C, Ponferrada A, Bermejo F, et al. Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory bowel disease. J Crohn’s Colitis.. 2017;11:792–800.CrossRefGoogle Scholar
  8. 8.
    Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004;2:309–313.CrossRefGoogle Scholar
  9. 9.
    Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340–354.CrossRefGoogle Scholar
  10. 10.
    Harboe M, Oettinger T, Wiker HG, Rosenkrands I, Andersen P. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun. 1996;64:16–22.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Helwig U, Muller M, Hedderich J, Schreiber S. Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients. J Crohn’s Colitis.. 2012;6:419–424.CrossRefGoogle Scholar
  12. 12.
    Papay P, Eser A, Winkler S, et al. Predictors of indeterminate IFN-gamma release assay in screening for latent TB in inflammatory bowel diseases. Eur J Clin Invest. 2011;41:1071–1076.CrossRefGoogle Scholar
  13. 13.
    Bartalesi F, Vicidomini S, Goletti D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J.. 2009;33:586–593.CrossRefGoogle Scholar
  14. 14.
    Andrisani G, Armuzzi A, Papa A, et al. Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. J Gastrointest Liver Dis: JGLD.. 2013;22:21–25.Google Scholar
  15. 15.
    Steffen RE, Caetano R, Pinto M, et al. Cost-effectiveness of Quantiferon(R)-TB gold-in-tube versus tuberculin skin testing for contact screening and treatment of latent tuberculosis infection in Brazil. PLoS One. 2013;8:e59546.CrossRefGoogle Scholar
  16. 16.
    Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn’s Colitis.. 2017;11:649–670.CrossRefGoogle Scholar
  17. 17.
    Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: diagnosis and medical management. J Crohn’s Colitis.. 2017;11:3–25.CrossRefGoogle Scholar
  18. 18.
    Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000;162:2033–2038.CrossRefGoogle Scholar
  19. 19.
    Baussano I, Williams BG, Nunn P, Beggiato M, Fedeli U, Scano F. Tuberculosis incidence in prisons: a systematic review. PLoS Med.. 2010;7:e1000381.CrossRefGoogle Scholar
  20. 20.
    Moss AR, Hahn JA, Tulsky JP, Daley CL, Small PM, Hopewell PC. Tuberculosis in the homeless: a prospective study. Am J Respir Crit Care Med. 2000;162:460–464.CrossRefGoogle Scholar
  21. 21.
    Dorman SE, Belknap R, Graviss EA, et al. Interferon-gamma release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014;189:77–87.PubMedGoogle Scholar
  22. 22.
    Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.CrossRefGoogle Scholar
  23. 23.
    Jauregui-Amezaga A, Turon F, Ordas I, et al. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohn’s Colitis.. 2013;7:208–212.CrossRefGoogle Scholar
  24. 24.
    Greveson K, Goodhand J, Capocci S, et al. Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNF alpha therapy. J Crohn’s Colitis.. 2013;7:412–418.CrossRefGoogle Scholar
  25. 25.
    Shahidi N, Fu YT, Qian H, Bressler B. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:2034–2042.CrossRefGoogle Scholar
  26. 26.
    Jeong DH, Kang J, Jung YJ, et al. Comparison of latent tuberculosis infection screening strategies before tumor necrosis factor inhibitor treatment in inflammatory arthritis: IGRA-alone versus combination of TST and IGRA. PLoS ONE. 2018;13:e0198756.CrossRefGoogle Scholar
  27. 27.
    Cardoso IP, de Almeida NP, Gotardo DR, Cardeal M, Santana GO. Tuberculin skin testing in inflammatory bowel disease patients from an endemic area of Brazil. Braz J Infect Dis. 2014;18:60–64.CrossRefGoogle Scholar
  28. 28.
    Mantzaris GJ, Tsironikos D, Tzanetakou X, et al. The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy. Scand J Gastroenterol. 2015;50:1451–1455.CrossRefGoogle Scholar
  29. 29.
    Qumseya BJ, Ananthakrishnan AN, Skaros S, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis. 2011;17:77–83.CrossRefGoogle Scholar
  30. 30.
    de Leon DP, Acevedo-Vasquez E, Alvizuri S, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol. 2008;35:776–781.Google Scholar
  31. 31.
    Abubakar I, Stagg HR, Whitworth H, Lalvani A. How should I interpret an interferon gamma release assay result for tuberculosis infection? Thorax. 2013;68:298–301.CrossRefGoogle Scholar
  32. 32.
    Campbell JR, Krot J, Elwood K, Cook V, Marra F. A systematic review on TST and IGRA tests used for diagnosis of LTBI in immigrants. Mol Diagn Ther.. 2015;19:9–24.CrossRefGoogle Scholar
  33. 33.
    Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis. 2008;27:907–913.CrossRefGoogle Scholar
  34. 34.
    Bermejo F, Algaba A, Chaparro M, et al. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study. Dig Liver Dis. 2013;45:733–737.CrossRefGoogle Scholar
  35. 35.
    Papay P, Primas C, Eser A, et al. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-alpha inhibitors. Aliment Pharmacol Ther. 2012;36:858–865.CrossRefGoogle Scholar
  36. 36.
    Thi AA, Abbara A, Bouri S, et al. Challenges in screening for latent tuberculosis in inflammatory bowel disease prior to biologic treatment: a UK cohort study. Frontline Gastroenterol.. 2018;9:7.CrossRefGoogle Scholar
  37. 37.
    Auguste P, Tsertsvadze A, Pink J, et al. Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and meta-analysis. BMC Infect Dis. 2017;17:200.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Renata F. Amorim
    • 1
  • Eduardo R. C. Viegas
    • 1
  • Antonio José V. Carneiro
    • 2
  • Barbara C. Esberard
    • 1
  • Evelyn S. Chinem
    • 1
  • Raquel S. Correa
    • 3
  • Luciana Rodrigues
    • 3
  • Marcelo Ribeiro-Alves
    • 4
  • Kelly S. Silva
    • 1
  • Heitor S. de Souza
    • 2
    • 5
    Email author
  • Ana Teresa P. Carvalho
    • 1
  1. 1.Department of GastroenterologyThe State University of Rio de JaneiroRio de JaneiroBrazil
  2. 2.Department of Internal Medicine, Division of GastroenterologyThe Federal University of Rio de JaneiroRio de JaneiroBrazil
  3. 3.Immunopathology LaboratoryThe State University of Rio de JaneiroRio de JaneiroBrazil
  4. 4.Evandro Chagas National Institute of InfectologyFIOCRUZRio de JaneiroBrazil
  5. 5.D’Or Institute for Research and EducationRio de JaneiroBrazil

Personalised recommendations